Enanta Pharmaceuticals, Inc.
ENTA
$13.24
-$0.26-1.93%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 14.36M | 17.16M | 18.62M | 15.13M | 18.31M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 14.36M | 17.16M | 18.62M | 15.13M | 18.31M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 14.36M | 17.16M | 18.62M | 15.13M | 18.31M |
| SG&A Expenses | 9.47M | 9.57M | 9.01M | 9.70M | 10.00M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 31.60M | 29.01M | 29.87M | 33.51M | 37.21M |
| Operating Income | -17.24M | -11.85M | -11.25M | -18.39M | -18.89M |
| Income Before Tax | -19.47M | -13.08M | -11.91M | -18.67M | -18.23M |
| Income Tax Expenses | 36.00K | 7.00K | 24.00K | 32.00K | 29.00K |
| Earnings from Continuing Operations | -19.50M | -13.09M | -11.94M | -18.70M | -18.26M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.50M | -13.09M | -11.94M | -18.70M | -18.26M |
| EBIT | -17.24M | -11.85M | -11.25M | -18.39M | -18.89M |
| EBITDA | -16.05M | -10.64M | -10.02M | -17.10M | -17.68M |
| EPS Basic | -0.67 | -0.45 | -0.42 | -0.87 | -0.85 |
| Normalized Basic EPS | -0.42 | -0.28 | -0.26 | -0.57 | -0.53 |
| EPS Diluted | -0.67 | -0.45 | -0.42 | -0.87 | -0.85 |
| Normalized Diluted EPS | -0.42 | -0.28 | -0.26 | -0.57 | -0.53 |
| Average Basic Shares Outstanding | 29.09M | 29.04M | 28.75M | 21.38M | 21.38M |
| Average Diluted Shares Outstanding | 29.09M | 29.04M | 28.75M | 21.38M | 21.38M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |